GLP-1 Study Receives Board Approval“All three of the GLP-1 and GIP drugs that Lexaria has tested during the last fifteen months have delivered successful results,” said Richard Christopher, CEO of Lexaria.
“We are establishing our technology as perhaps the most effective drug delivery technology in the world to date, for weight loss drugs such as GLP-1.”
Approved for use by diabetics to control blood sugar, liraglutide has also evidenced an ability to slow cognitive decline in a Phase 2b clinical trial, and reduce shrinkage of those areas of the brain that control memory, learning, and language by nearly 50% as compared to placebo.